AnaptysBio, Inc. - Common Stock (NQ:ANAB)

44.51 +0.16 (+0.36%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist

Price and Volume

Volume	300,444
Open	45.35
Bid (Size)	42.20 (200)
Ask (Size)	46.55 (300)
Prev. Close	44.35
Today's Range	44.20 - 46.56
52wk Range	12.21 - 46.56
Shares Outstanding	27,433,359
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Anaptys Announces Participation in December Investor Conferences

November 25, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

AnaptysBio Inc (NASDAQ:ANAB) Screens as a High-Growth Momentum Leader ↗

November 22, 2025

AnaptysBio (ANAB) is a high-growth biotech stock with a strong technical uptrend, surging revenue, and impressive relative strength.

Via Chartmill

Performance

YTD	+233.2%	+233.2%
1 Month	+31.0%	+31.0%
3 Month	+100.6%	+100.6%
6 Month	+91.9%	+91.9%
1 Year	+94.5%	+94.5%

More News

ANAB Stock Falls After It Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal ↗

November 21, 2025

Via Stocktwits

Anaptys Announces $100 Million Stock Repurchase Plan

November 21, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level ↗

September 30, 2025

Via Stocktwits

Why Is Eli Lilly’s Stock Slipping Premarket? ↗

September 17, 2025

Via Stocktwits

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

November 21, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup ↗

November 13, 2025

Via Chartmill

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study ↗

November 10, 2025

Via Benzinga

Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run ↗

November 10, 2025

Via Investor's Business Daily

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

November 10, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys Announces Participation in November Investor Conferences

November 04, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

November 04, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

October 29, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

October 13, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

Wall Street Climbs Despite Shutdown Risk — Pfizer and CoreWeave Shine Bright ↗

October 01, 2025

Via Chartmill

Here are the top movers in Tuesday's session. ↗

September 30, 2025

Via Chartmill

AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗

September 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 30, 2025

Via Benzinga

United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗

September 30, 2025

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

September 30, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 29, 2025

Via Benzinga

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

September 29, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

September 29, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

Anaptys Announces Participation in September Investor Conferences

August 27, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is AnaptysBio, Inc. - Common Stock publicly traded?

Yes, AnaptysBio, Inc. - Common Stock is publicly traded.

What exchange does AnaptysBio, Inc. - Common Stock trade on?

AnaptysBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for AnaptysBio, Inc. - Common Stock?

The ticker symbol for AnaptysBio, Inc. - Common Stock is ANAB on the Nasdaq Stock Market

What is the current price of AnaptysBio, Inc. - Common Stock?

The current price of AnaptysBio, Inc. - Common Stock is 44.51

When was AnaptysBio, Inc. - Common Stock last traded?

The last trade of AnaptysBio, Inc. - Common Stock was at 12/08/25 04:00 PM ET

What is the market capitalization of AnaptysBio, Inc. - Common Stock?

The market capitalization of AnaptysBio, Inc. - Common Stock is 1.22B

How many shares of AnaptysBio, Inc. - Common Stock are outstanding?

AnaptysBio, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.